Loading...
Effect of Orally Administered Microencapsulated FA-Producing L. fermentum on Markers of Metabolic Syndrome: An In Vivo Analysis
Bhathena, Jasmine Martoni, Christopher Malhotra, Meenakshi Kulamarva, Arun Urbanska, Aleksandra Malgorzata Paul, Arghya Prakash, Satya Tomaro-Duchesneau, Catherine
Bhathena, Jasmine
Martoni, Christopher
Malhotra, Meenakshi
Kulamarva, Arun
Urbanska, Aleksandra Malgorzata
Paul, Arghya
Prakash, Satya
Tomaro-Duchesneau, Catherine
Citations
Altmetric:
Abstract
Ferulic Acid (FA) is a natural phenolic acid produced by a number of lactic acid bacteria. FA has a number of
beneficial properties, including: antioxidant activity, anti-tumorigenic properties and cholesterol-lowering capabilities.
Our group has previously screened lactobacilli for FA production, and selected L. fermentum ATCC 11976 (L.f.
11976) as one of the best producers. Alginate-polylysine-alginate (APA) microencapsulation has proven successful
for the oral delivery of this strain to the colon, where production of FA is greatest. The aim of this study was to
investigate the role of APA microencapsulated L.f. 11976 to modulate markers of metabolic syndrome. The antioxidant
activity, as a potential mechanism of action to treat/prevent metabolic syndrome of free and microencapsulated L.f.
11976 was quantified. A high-fat fed BioF1B Golden Syrian hamster model was used to investigate the effects of
orally administered microencapsulated L.f. 11976 on markers of metabolic syndrome. Results demonstrate that
the microencapsulated L.f. 11976 formulation greatly reduced the adiposity index (p = 0.0014), serum insulin (p =
0.0042), insulin resistance (p = 0.0096), glycosylated albumin (p = 0.00013), serum leptin (p = 0.048), serum uric acid
(p =0.025) serum total cholesterol (p = 0.024), serum esterified cholesterol (p = 0.0328) and free non-esterified fatty
acid (p = 0.029) levels in the treated animals. This research indicates that the probiotic L.f. 11976 microencapsulated
formulation may significantly delay the onset of insulin resistance, hyperglycemia, hyperinsulinemia, dyslipidemia
and obesity, indicating a lower risk of diabetes and cardiovascular disease. We propose and discuss the potential
mechanism(s) of action by which FA is acting. With these in mind, further in vivo studies are required to validate the
therapeutic effects of the formulation and to investigate the mechanism(s) of action by which the probiotic formulation
is acting.
Description
Date
2012-05-25
Journal Title
Journal ISSN
Volume Title
Publisher
OMICS International
Research Projects
Organizational Units
Journal Issue
Keywords
Ferulic acid, Microencapsulation, Metabolic syndrome, Lactobacillus, Type-2-diabetes mellitus, Obesity
Citation
Bhathena, Jasmine, Catherine Tomaro-Duchesneau, Christopher Martoni, Meenakshi Malhotra, Arun Kulamarva, Aleksandra Malgorzata Urbanska, Arghya Paul, and Satya Prakash. "Effect of Orally Administered Microencapsulated FA-Producing L. Fermentum on Markers of Metabolic Syndrome: An In Vivo Analysis." Journal of Diabetes & Metabolism J Diabetes Metab 01.S2 (2012): n. pag. http://dx.doi.org/10.4172/2155-6156.S2-009